EDI – Kosten der Gewalt in Paarbeziehungen

 EDI – Kosten der Gewalt in Paarbeziehungen Bern, 19.11.2013 – Kosten in der Höhe von mindestens 164 Millionen Franken jährlich entstehen der Gesellschaft durch Gewalt in Paarbeziehungen. Ein im Auftrag des Eidgenössischen Büros für die Gleichstellung von Frau und Mann EBG erarbeiteter Forschungsbericht weist erstmals systematisch die Folgekosten von Gewalt in Paarbeziehungen aus und zeigt auf, in welchen Kostenbereichen diese anfallen.Eidgenössisches Departement des Innern

Roche presents lampalizumab biomarker data from phase II study in advanced form of dry macular degeneration

a  • MAHALO phase II data previously showed a reduction in disease progression in patients with geographic atrophy, the advanced form of dry age-related macular degeneration (AMD)• Strongest treatment effect was observed in patients positive for the Complement Factor I (CFI) genetic biomarker• Roche will continue to investigate the biomarker strategy to identify people who would benefit most from treatment with lampalizumabRoche (SIX: RO, ROG; OTCQX: RHHBY) today announced additional encouraging phase II results with lampalizumab from the MAHALO study in patients with geographic atrophy (GA). GA is characterised by the irreversible loss of retinal tissue in the macula that results in permanent blind spots in a patient’s central vision. In a sub-population of GA patients positive for the Complement Factor I (CFI) biomarker, who received monthly lampalizumab, data from an exploratory analysis show a 44 percent decrease (p<0.005) in the rate of disease progression at 18 months. When lampalizumab was administered every other month, the rate of disease progression was decreased by 18 percent (p=0.23) in the biomarker defined sub-group of patients. No unexpected or unmanageable serious adverse events were detected in the MAHALO study. These data were presented at the 2013 Retina Subspecialty Day Session of the Annual Meeting at the American Academy of Ophthalmology in New Orleans, Louisiana, USA.“The phase II results are good news for patients with geographic atrophy, a major vision-impairing disease where there is currently no treatment available,” said Richard Scheller, Ph.D., Head of Genentech Research and Early Development. “These preliminary biomarker data show the CFI biomarker could help identify patients most likely to respond to treatment with lampalizumab.”AMD has a strong genetic component with genetic factors accounting for more than 50 percent of the risk for the disease.(1) Genetic polymorphisms in the complement pathway have been implicated in the development of AMD including GA. In the MAHALO study, 57 percent of genotype samples collected from 93 patients were positive for the CFI biomarker. Although the phase II study was relatively small, these results suggest the CFI biomarker is both prognostic for GA area progression and predictive for lampalizumab treatment response. Only MAHALO patients that were positive for the CFI biomarker showed a treatment effect with lampalizumab.AMD is a leading cause of blindness in adults over 55 years of age in the developed world. There are two forms of AMD, wet AMD and dry AMD. GA, the advanced form of dry AMD, affects more than 8 million people worldwide.(2) While therapies have become available for wet AMD, currently there are no approved treatments for people with GA.About the MAHALO studyThe phase II trial was a multi-centre, randomised, single-masked, controlled study of the safety, tolerability and evidence of activity of lampalizumab in patients with GA associated with AMD. Study participants received lampalizumab injections in one eye either monthly or every other month for 18 months. The primary endpoint was change of GA area from baseline to month 18 compared with control, as assessed with fundus autofluorescence (FAF). Four genetic biomarkers were examined in MAHALO, including complement factor H (CFH), C3, C2/CFB and CFI. In the MAHALO study, most patients had a background of CFH and C2/CFB.Lampalizumab showed a 20.4 percent reduction rate in the area of geographic atrophy at 18 months that was statistically significant (p=0.1170) per pre-specified protocol criteria in patients with this advanced form of dry AMD. The efficacy assessed by FAF was observed in those receiving monthly injections beginning at month six and maintained through month 18. A secondary endpoint of change in GA area from baseline to month 18 was assessed by colour fundus photographs and these results confirmed the FAF primary endpoint outcome.In a sub-population of GA patients treated monthly with lampalizumab that were positive for the CFI exploratory biomarker, the GA progression rate was decreased by 44 percent at 18 months (p<0.005). Safety outcome measures included incidence and severity of ocular and non-ocular (systemic) adverse events (AE). Intraocular inflammation AE rates and intraocular pressure elevation AE rates were consistent with Lucentis rates for these AEs in wet AMD. The most frequently reported AEs in the study eye were associated with the injection procedure. There were no intraocular infections, no unexpected or unmanageable serious AEs, no death or ocular serious AEs suspected to be caused by study drug and no ocular serious AEs in study eye leading to treatment discontinuation.About lampalizumabLampalizumab is being investigated to determine its effect on the progression of GA associated with advanced dry AMD.  The molecule is an antigen-binding fragment (Fab) of a humanised, monoclonal antibody directed against complement factor D. Complement factor D is a rate-limiting enzyme involved in the activation of the alternative complement pathway (ACP). The ACP is a component of the immune system’s natural defence against infections. Genetic polymorphisms as well as hyperactivity of the ACP have been implicated in the development of AMD including GA.About geographic atrophy (GA)GA is an advanced form of AMD and is a progressive, irreversible and blinding disease. GA is responsible for irreversible severe vision loss in approximately 20 percent of all patients with AMD.(3-4) Visual impairment associated with GA tends to affect both eyes in many individuals. GA patients report visual problems with reading, recognising faces, and activities in low illumination. GA represents a significant unmet medical need as there are no approved treatments for this condition.About Roche in ophthalmologyRoche’s ophthalmology medicines include Lucentis (ranibizumab injection), which is indicated in the United States for the treatment of wet age-related macular degeneration (wet AMD), macular edema following retinal vein occlusion (RVO) and diabetic macular edema (DME).Lucentis was discovered by Genentech and continues to be developed by Genentech and Novartis for diseases or disorders of the eye. Genentech retains commercial rights in the U.S. and Novartis has exclusive commercial rights for the rest of the world.About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, ophthalmology, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.All trademarks used or mentioned in this release are protected by law.References:1. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age related maculopathy. Am J Ophthalmol 1997; 123: 199-206.2. Rudnicka, A. et al,”Age and Gender Variations in Age-related Macular Degeneration Prevalence in Populations of European Ancestry: A Meta-analysis,”Ophthalmology, 2012; 119:571–580.3. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL III; Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 2005;112:533–9.4. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina 2010;30:1350–67.With best regards,Roche Investor RelationsDr. Karl MahlerPhone: +41 61 68-78503e-mail: karl.mahler@roche.comDr. Sabine BorngräberPhone: +41 61 68-88027e-mail: sabine.borngraeber@roche.comLuís Correia Ph.D.Phone: +41 61 68-75284e-mail: luis.correia@roche.comTamer Farhan Ph.D.Phone: +41 61 68-82552e-mail: tamer.farhan@roche.comDr. Nina MojasPhone: +41 61 68-71300e-mail: nina.mojas@roche.comElhan Webb, CFAPhone: +41 61 68-89630e-mail: elhan.webb@roche.comInvestor Relations North AmericaThomas Kudsk LarsenPhone: +1 650 467 2016e-mail: larsen.thomas@gene.comNina GoworekPhone: +1 650 467 8737e-mail: goworek.nina@gene.comEkaterine Kortkhonjia Ph.D.Phone: +1 650 467 5873e-mail: kortkhonjia.ekaterine@gene.com

Gurit to present its product offering for superior FST behaviour and excellent surface finishing for parts and panels at Railway and Mass Transit Interiors Expo 2013, Germany

a With over 30 years of experience as a prime composite materials supplier and engineering partner to a broad array of industrial markets including high-end applications such as today’s most advanced passenger aircraft or weight and performance optimised composite wind turbine blades, Gurit also understands the most pressing needs of the rail market. Key parameters of passengers’ safety are the fire, smoke and toxicity (FST) performance of the materials chosen. All these aspects can be optimised by using state-of-the-art composite materials that are ideally suited to manufacture weight-optimised laminate structures, sandwich or crushed-core components like e.g. fairings, windows, ceilings and floor panels that exceed the customers’ performance criteria and the most stringent safety requirements. Exhibiting on stand 4170, Gurit will be showcasing its manufacturing expertise to the rail market, which enables products like prepregs, structural core materials and adhesives to be tailored to customers’ exact requirements. Gurit’s prepregs combine advanced resin formulations with various kinds of reinforcements, hybrids or unidirectional (UD) tapes. Two of these products being highlighted at the show are:PH 840 PH 840 is a low volatile phenolic and low moisture content prepreg system which ensures the production of parts and panels with excellent surface and provides excellent FST properties. Gurit's PH 840 is one of the best commercially available phenolic system thanks to both its process ability properties and the good quality surface that can be achieved on final parts. SPRINT™ ST 70 or ST 70 FR (fire retardant) Gurit’s innovative SPRINT™ product range uses a high flow, low tack epoxy prepreg ideally suited to the manufacture of exterior structures in combination with Corecell™ foam core. The major benefit of SPRINT™ is that it enables all of the air to be removed from the laminate prior to fibre wet out and resin cure. Gurit’s sales and technical staff will be available on stand 4170 to discuss the range of advanced composite materials available for the Rail and Mass Transit markets.

Swiss Re General news release: Swiss Re unveils new brand strategy and modernized logo as it celebrates 150 year anniversary

The day of its official anniversary of 150 years, leading re / insurance Swiss Re unveils a new brand strategy and a modernized logo. The new brand promise "We are smarter together" aims to support Swiss Re ambition for growth companies and differentiation on the market.

Group CEO Michel M. Liès said: "for the last 150 years, it was Swiss Re company to allow people to turn the pioneer of the ideas in reality, or get back on the right track when things go wrong. We had our anniversary at the opportunity to review our brand positioning and launch a new brand promise: 'We are smarter together' is public statement of Swiss Re which highlight the spirit of partnership of our knowledge-based society, committed to helping customers succeed. Our mutual success will actually address the persistent phenomenon of underinsurance in many regions of our planet and that always specific protection gaps of the face, companies and also countries. »

Launch of the new brand strategy and the logo modernized Swiss Re
Revised Swiss Re branding has been defined after extensive consultation with internal and external stakeholders. An economic and strategic asset important, it must be protected and improved continuously. Swiss Re is strongly associated with attributes such as the expertise, global, integrity, strong financial and heritage. The Executive Committee of the Group decided to build on existing strengths, but also slightly reposition the company in the future, in order to present it as more emotional, focusing on the benefits and collaborative. This program aims to enable the company to stand farther out on the market.

Part of the change is the Swiss Re logo modernization to make it a more powerful and more distinct symbol on markets around the world. While the so-called pillars be maintained for stability, the new roundel expresses customer orientation and worldliness. The Board of Directors and the Group Executive Committee also approved a strategy of 'one-mark' for the whole of the group with its three business units.

Publication of the book on the history of Swiss Re
Swiss Re also published a book on the history of the company and the industry. Produced in German and English, she traces the evolution of a small start-up company in a small office in the old town of Zürich in a giant industry with more than 11,000 employees in more than 60 locations. Richly illustrated with dozens of photographs and reprints, the publication is divided into three parts: it opens an overview of the development of the insurance sector, describes the journey of the reinsurance industry and then ends in the history of Swiss Re itself. The book was written by Peter Borscheid, Professor Emeritus of social and economic history at the University of Marburg (insurance), David Gugerli, Professor of history of technology at ETH Zurich (reinsurance) and Tobias Straumann, lecturer at the research centre for economic and social history at the University of Zurich (Swiss Re). It is edited by Harold James, Professor of history at Princeton University, USA and has a foreword by Walter Kielholz, Chairman of the Swiss Re Group.

"As a reinsurer, Swiss Re had to internationalise its activities from the outset in order to diversify its portfolio of risks. While most of the major disasters that struck in the past have left traces in the books of the company: the San Francisco of 1906 earthquake, sinking hurricanes Titanic, the great depression, Andrew and Katrina and 9/11. "At the same time, the company has always demonstrated a deep attachment to the Switzerland and benefited from the forces and the values that go with the brand Switzerland", explains Tobias Straumann.

Contact:
Rolf Tanner
Head of Media Relations
media_relations@SwissRe.com
Phone + 41 43 285 7171

For more information about Swiss Re please visit our website www.swissre.com.

Nestlé joins alliance for responsible plant-based plastics

a Nestlé has announced that it will work in partnership with the World Wildlife Fund (WWF) and seven consumer firms to encourage the responsible development of bioplastics, derived from plant materials.Along with Nestlé, the Bioplastic Feedstock Alliance (BFA) will include key fast-moving consumer goods firms The Coca-Cola Company, Danone, Ford, H.J. Heinz Company, Nike, P&G, and Unilever.As consumers across the world seek sustainable alternatives to petroleum-based products, the alliance will aim to guide the responsible selection and harvesting of agricultural materials - such as sugar cane, corn, bulrush, and switchgrass - used to make bioplastics.Real alternatives"Joining the alliance means we will be able to help build a more sustainable future for the bioplastics industry whilst addressing issues such as land use, food security and biodiversity," said Nestlé's Global Research and Development Sustainability Manager, Anne Roulin.BFA intends to bring together leading experts from industry, academia and civil society to develop and support informed science, collaboration, education, and innovation to help guide the evaluation and sustainable development of materials that can be made into bioplastics.Critical for conservation"Ensuring that our crops are used responsibly to create bioplastics is a critical conservation goal, especially as the global population is expected to grow rapidly through 2050," said Erin Simon, of WWF.Already, bioplastics made from sugar cane and other plant-based materials are used in Nestlé's product portfolio. Since early 2012, for example, several sizes of VITTEL bottled water have been packaged in an innovative PET bottle made from 30% plant-based material.Nestlé is particularly interested in second generation bioplastics, made, for example, from the by-products of forestry, agriculture or the food chain - such as molasses or cane residue - or non-food sources such as algae, cellulose and waste products.Related information:The Bioplastics Feedstock Alliancehttp://www.bioplasticfeedstockalliance.org/Nestlé and Environmental Sustainability: Packaginghttp://www.nestle.com/csv/environmental-sustainability/packagingNestlé and Creating Shared Valuehttp://www.nestle.com/CSVVittel Waterhttp://www.vittel.com/fr/index.htmRead more about Nestlé and bioplastics:Nestlé sees bioplastics as the future of packaginghttp://www.nestle.com/media/newsandfeatures/nestle-sees-bioplastics-as-future-of-packagingNestlé Waters and bioplasticshttp://www.nestle-waters.com/environment/bottled-water-packaging/pet-bottles-bio-plasticsNestlé launches bioplastic caps for milk brands in Brazilhttp://www.nestle.com/Media/NewsAndFeatures/Nestle-launches-bioplastic-caps-for-milk-brands-in-BrazilMedia enquiries Tel: +41 21 924 2200 Email: Nestlé Corporate Media Relations

Schweiter verkauft Liegenschaft in La Chaux-de-Fonds

a Horgen, 15. November, 2013 - Schweiter Technologies veräussert die nicht betriebsnotwendige Liegenschaft in La Chaux-de-Fonds an Procimmo Swiss Commercial Fund.Der Verkaufspreis beträgt CHF 18.3 Mio - mit dem Verkauf erzielt Schweiter Technologies einen Buchgewinn im tiefen einstelligen Millionenbereich.Procimmo Swiss Commercial Fund ist ein auf kommerzielle Bauten spezialisierter Immobilienfonds und ist an der Schweizer Börse SIX Swiss Exchange kotiert.Für weitere Informationen:Martin Klöti, Head of Management ServicesTel. +41 44 718 33 03, Fax +41 44 718 34 51, martin.kloeti@schweiter.comSchweiter Technologies AG, Neugasse 10, CH - 8810 Horgen, SwitzerlandTelefon +41 44 718 33 03 Fax +41 44 718 34 51 info@schweiter.comhttp://www.schweiter.com/Die Medienmitteilung ist auf folgendem Link als PDF abrufbar:

Rock in the new subcutaneous formulation RoACTEMRA receives positive opinion from the CHMP in Europe moderate to severe rheumatoid arthritis

AppId is over the quota
© 2000-2013 Armando Guglielmetti

Désolé, que je ne pouvais pas lire le contenu fromt cette page.

Global News Nestlé monthly Roundup-2nd edition

Meet Cesar, one of the 100,000 coffee growers in the NESCAFÉ Plan Colombia. He explained how the initiative has helped a better bean and improve life on his farm coffee plantation.Read more... Little more than a year, Nestlé began working with the Fair Labor Association to tackle the problem of child labour in the cocoa in Côte d'Ivoire sector. Discover what we have done since we started and how our cocoa Plan improves cocoa farmers lives there. Read more... 4.4% of organic growth, the fiscal Outlook has confirmed.Paul Bulcke, Nestlé CEO: "our real internal growth regained momentum and widened through the categories, target prices and geographies." Read more... Nestlé contributes to micronutrient deficiencies in developing countries by mapping the nutritional gaps. The process, called nutritional landscaping, reveals where there is a need of micronutrients including iodine, iron, zinc and vitamin a. Read more... A survey of 70,000 consumers in 15 major international markets found that Nestlé is the fifth mark more loved in the world. The rankings are the result of a research project for ten years, including the global survey of more than 600 of the leading brands of the world. Read more...

Annual report of CHC 2012/13; Satisfactory result due to non-recurring items

The overall performance in the energy segment decreased from the previous year to 42.8 million Swiss francs or 8.0% to 492.7 million Swiss francs. It is because of the low rates of electricity for residential and business customers, but also considerably deprived the market price for transactions of optimization. Provisions for the supply of energy expensive contracts of 37.8 million Swiss francs had to be registered to the base in the medium term should also low sale price. A lower yield of 0.9 million Swiss francs due to a weaker performance from federal service and funds for nuclear waste disposal. In the same period last year, reached an excess return of 12.8 million Swiss francs. This energy poses a 55.1 percent more low surplus or deficit of the previous year in the segment with 27.9 million Swiss francs.

Reversal of provisions leads to higher earnings

In the segment, the judgment of the supreme Administrative Court of 29 January 2013 led the networks to a reversal of provisions for regulatory procedures. CHC had appeals against the part of the Federal Commission of electricity and solved successfully the provision for qualified of 46.6 million Swiss francs. Through the sale of shares in CHCs Grid AG, a capital gain of 5.1 million Swiss francs is reflected in the segment of the networks. Through these two one-off effects, the segment complete networks over the previous year, with operating profit more than CHF 63.8 million, 103.9 million Swiss francs.

The installation segment increases the overall performance of 8.9% for FY 2012/13 to 131.4 million Swiss francs. Operating income can be increased at 61.8%, representing 4.2 million francs. The reasons for this positive development within an improved order and cost management, a good load and strong weight gain.

After the structural adjustment of the pension fund PKE Behindertenzentrum energy has arisen a one-time reduction of interest charges to CHF 16.8 million due to the actuarial calculation of active retirement and pension liabilities according to IAS 19 for the CKW group.

2013/14 Views

CSC is still deeply wholesale market prices for power and hard by the rules predictable framework conditions and the requirements of the policy for the current fiscal year. In particular, decisions pending to fund federal decommissioning and waste disposal for nuclear facilities funds can strongly influence the cost of production. In addition, the development of the economic and financial market uncertain in Switzerland and Europe can influence the result of operation of the CSC.

The CKW group key figures

EBIT margin (in % of the)
Overall performance)

Equity of minority interests

Investment in a tangible and intangible. Equipment

* PP: percentage points

2014 General meeting

The Board of Directors proposes a consistent dividend of 4.50 CHF per action the General Assembly by January 31, 2014. The dividend shall be paid on 7 February 2014.

After about ten years of membership of the Board of Directors of CSC, which has six as Chairman of the Board of Directors, Heinz Karrer said yesterday his resignation. The Board of Directors of the General Assembly of Andrew Walo, February 1, 2014 new CEO of Axpo offers group, choice as successor and President of the Group of experts.

The annual report of CHC 2012/13 (annual report and financial statements) is the SCC Web site:

www.CKW.ch > investors > annual report.

Media office

Central Central-Swiss AG
Postfach, 6002 Lucerne

Phone 0800 259 259

Communications@CKW.ch

Novartis announces positive clinical trials for novel H7N9 vaccine results

85% of patients immunologically protected after receiving the second dose of experimental cell culture vaccine when combined with proven adjuvant MF59 ®The vaccine currently in production on a large scale, highlighting the rapid reaction of the FDA approved cell culture technology novel capacity135 laboratory confirmed cases and 45 deaths due to the virus of the H7N9 since the emergence in March, according to the world Organization of health [1]Basel, Switzerland, 14 November 2013 -Novartis announced today preliminary results of a Phase 1 clinical study with its vaccine exclusive cell culture for virus of avian influenza H7N9 involving 400 healthy volunteers (aged 18-64). The data show that 85% of subjects with a protective immune response after two doses of vaccine with adjuvant 15 ug MF59. Only 6% of subjects have a protective when response received two doses of adjuvanted vaccine UN 15ug. The complete set of test data will be submitted to a journal for publication in the near future.The vaccine was produced using cell culture on a large scale manufacturing technology, an alternative technology which can significantly speed up the production of vaccines against the traditional egg-based methods.[2] The cell culture technology uses an eggs line instead of the chicken of mammalian cells well characterized to grow virus strains.[3]"This rapid reaction underlines our position as leader in pandemic preparedness," said Andrin Oswald, Division Head, Novartis Vaccines. "Thanks to our investments in innovative production and adjuvant technologies, we are now able to offer a protection solution for a potentially deadly pandemic virus within a few months after the appearance of the virus H7N9."Reports of infection H7N9 first appeared in China in March 2013. Novartis, along with its partners at the Craig Venter Institute, synthesized the virus strain several days after that, it was shared with global researchers by the Chinese Centers for Disease Control. Novartis then produces clinical batches of first instance, has started clinical trials in August and launched a production on a large scale in its facilities in Holly Springs (NC), United States, and Marburg (Germany) in October.This project was funded in part with federal funds from the Office of the Assistant Secretary for preparedness and response, Biomedical Advanced Research and Development Authority, under contract no. HHSO1002012000141DisclaimerThis press release contains forward-looking statements that can be identified by words such as "will be investigative, acting" or similar expressions, or by express or implied discussions regarding potential effectiveness for Novartis H7N9 avian flu vaccine, or regarding potential future revenues from Novartis H7N9 vaccine against avian influenza. You should not place undue reliance on these statements. These forward-looking statements are based on current beliefs and expectations of management regarding future events and are subject to known and unknown risks and uncertainties. If one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those contained in the forward-looking statements. There may be no guarantee that Novartis H7N9 avian influenza vaccine will receive regulatory approval or be marketed successfully in the future. In particular, the expectations of management regarding Novartis H7N9 avian influenza vaccine could be affected by, among other things, the uncertainties inherent in research and development, unexpected clinical trial results, including additional analysis of existing clinical data; unexpected regulatory actions or delays or Government regulation generally; the company's ability to obtain or maintain exclusive intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including the ongoing price pressures; problems of unexpected manufacturing and other risks and factors current al Novartis AG 20-F Form filed with the Securities and Exchange Commission. Novartis provides the information contained in this press release as of this date, and undertakes no obligation to update the forward-looking statements contained in this press release as a result of new information, future events or otherwise.Subject of NovartisNovartis provides innovative health solutions that respond to the changing of patients and companies needs. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, of eye care, savings of generic pharmaceuticals, preventive vaccines and diagnostic tools, products of over-the-counter health and animals. Novartis is the only multinational one with leading positions in these areas. In 2012, the Group had sales net of $ 56.7 billion, while R & D in all of the Group amounted to approximately 9.3 billion USD (EUR 9.1 billion excluding depreciation and amortization costs). Novartis group companies employ approximately 133,000 associates equivalent full-time and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.Novartis is on Twitter. Sign up to follow the @Novartis to http://twitter.com/novartis.References[1] www.who.int/ influenza/human_animal_interface/influenza_h7n9/en/index.html[2] U.S. Department of Health and Human Services. "HHS Awards contracts totaling more than 1 billion $ in the flu cell. '' 2006 Available at: http://archive.hhs.gov/news/press/2006pres/20060504.html.[3] Gravenstein, Arvydas et al. Culture technique of novel mammalian cells for consistent production of a trivalent subunit vaccine well-tolerated and immunogenic. Vaccine. Flight 27. Number 43. 9 October 2009: 6022-6029. Available at: http://www.sciencedirect.com/science/article/pii/S0264410X09011177. Retrieved October 3, 2012.# # #Novartis media relationsOnline Media Centre: + 41 61 324 2200 e-mail: media.relations@novartis.comFor Novartis multimedia content, visit www.thenewsmarket.com/ NovartisFor questions about the site or registration required, please contact: journalisthelp@thenewsmarket.com.Novartis investor relations

Actelion informs later in a legal dispute with Asahi

AppId is over the quota
ALLSCHWIL, Suisse - 19 décembre 2013 - Actelion Ltd (SIX : ATLN) a annoncé aujourd'hui que la Cour d'appel de Californie prononcée en novembre 2011 contre Actelion final Court of California (procédure no CIV478533 devant la Cour d'appel de Californie) a confirmé. Cette dernière phrase s'élevait à une amende d'un montant de USD 407325 millions. Y compris astreintes sont 30 millions par le biais de différents cadres supérieurs de la compagnie s'élevant à USD. En outre la Cour a fixé les paiements d'un montant de 8,3 millions d'USD pour les intérêts et autres frais pour la période antérieure à la détermination de la peine.

La société et ses conseillers externes sont convaincus que la décision de la Cour d'appel est appuyée par des faits et qu'il est juridiquement incorrecte. La société est donc fermement convaincue qu'il existe des raisons importantes, faire appel de cette décision. En particulier, la décision que l'intervention d'une société mère dans une entente contractuelle, une filiale est considérée comme irrecevable et elle ne peut être tenue responsable de cela n'est pas conforme à la décision de la Cour suprême de Californie dans l'affaire appliquées equipment Corp.

La compagnie prendra toutes les mesures nécessaires, à soumettre une demande de réexamen de la décision de la Cour d'appel de la Cour suprême de Californie.

###

 NOTES POUR LES RÉDACTEURS

LeMotion de procédure

Le 19 novembre 2008, une action en justice contre Actelion Ltd et ses filiales Actelion pharmaceuticals USA, Inc., Actelion Pharmaceuticals Ltd, société de portefeuille d'Actelion U.S., CoTherix, Inc. ("CoTherix") et trois cadres supérieurs de la compagnie a déposé la demanderesse Asahi Kasei Pharma Corporation (« Asahi ») à la Cour, dans l'état de Californie, aux États-Unis. Le différend se réfère à une licence complétée entre Asahi et CoTherix pour l'ingrédient actif de l'accord de Fasudil et de développement qui a été suspendue après l'acquisition de CoTherix en 2007.

La décision du jury

Le 4 mai 2011, Asahi Kasei Pharma ("Asahi") ont été attribués à 547 millions de paiement de dommages-intérêts par un jury composé de maximum de USD. En outre, le jury a condamné individuels cadres supérieurs de la société 30 millions d'amendes s'élevant à USD.

Demandes soumises après la conclusion de la procédure

Actelion a présenté une série d'amendements après la proclamation du jugement que la Cour a confirmé en partie, pour que le verdict final--enregistrées dans les résultats de l'ensemble de l'année pour la société 385 millions en 2011 - une compensation d'un montant de USD. En outre, trois cadres supérieurs de la société ont été purgeant une peine de 30 millions de pénalités d'un montant de USD.

L'appel

L'appel a été en décembre 2011 à la Cour d'appel (procédure no CIV478533) de Californie a déposé, les plaidoiries ont été échangés et l'audience a eu lieu le 21 novembre 2013. La Cour d'appel de Californie a confirmé le jugement modifié, prononcé en novembre 2011 contre Actelion en Californie. La compagnie prendra toutes les mesures nécessaires, à soumettre une demande de réexamen de la décision de la Cour d'appel de la Cour suprême de Californie.

Actelion Ltd

Actelion Ltd est une société biopharmaceutique dont le siège est à Allschwil/Bâle, Suisse. Premier médicament de Actelion, Tracleer ® (Bosentan), est un antagoniste des récepteurs de l'endothéline double approuvé pour le traitement de l'hypertension artérielle pulmonaire sous forme de comprimés. Actelion commercialise Tracleer ® par le biais de ses bureaux dans les principaux marchés internationaux, comme aux États-Unis (dont le siège est à South San Francisco), l'Union européenne, Japon, Canada, Australie et de la Suisse. Actelion, fondée en 1997, est une entreprise leader dans l'exploration de l'endothélium. L'endothélium sépare la paroi vasculaire de la circulation sanguine. Avec plus de 2 300 employés, Actelion met l'accent sur la découverte de médicaments innovants dans les régions où les besoins médicaux non satisfaits, à développer et commercialiser. Actelion actions sont à la SIX Swiss Exchange dans le contexte de la blue chips Index SMI (indice du marché Suisse SMI ®) échangé (symbole : ATLN).

Pour plus d'informations, veuillez communiquer avec :

Roland Haefeli
Senior Vice President, responsable des relations avec les investisseurs et affaires publiques
Actelion Pharmaceuticals Ltd, commercial allée 16, CH-4123 Allschwil
+ 41 61 565 62 62
+ 1 650 624 69 36
www.Actelion.com

Les informations ci-dessus contient certains énoncés prospectifs concernant les affaires de la compagnie, qui "sera grâce à l'utilisation de termes tels que « estimer », « croire », « prévoit », »,"devrait","' d","recherche","en attente","s'attend"ou des expressions similaires et peuvent être identifiées par analyse de la stratégie, des plans ou des intentions. Ces déclarations comprennent des descriptions de programmes de recherche et de développement de la société et donc dans les dépenses connexes, les descriptions des nouveaux produits, ce qui devrait être mis sur le marché par la société et la demande pour ces produits déjà existants ou disponibles uniquement sous Vista. Ces énoncés prospectifs reflètent les vues actuelles de la compagnie au sujet de cet événements futurs et sont soumis à des risques connus et inconnus, des incertitudes et des hypothèses. Plusieurs facteurs peuvent influencer le rendement efficace, des résultats ou des performances, donc ils peuvent différer considérablement de ces déclarations prévisionnelles mentionnées explicitement ou implicitement. Devrait être l'un ou plusieurs de ces risques ou les hypothèses s'avéraient être incorrectes, les résultats effectifs de la société peuvent différer sensiblement de l'attendre.

Meyer Burger concludes a strategically important contract with a leading Asian cell manufacturer for the supply of coating systems for its first heterojunction line in the market. The order volume is CHF 14 million.

PostFinance partecipa al programma US

AppId is over the quota

13.12.2013, Bern

PostFinance a décidé de participer au programme de la pièce de litiges fiscaux avec les États-Unis. Vous devez vous inscrire à la fin de décembre, dans le délai prescrit, au ministère de la Justice (MJ) pour une participation dans la catégorie 2. PostFinance réserve la possibilité de demander à une date ultérieure une « Non-Target-lettre » selon la catégorie 3.

La décision en faveur de la catégorie 2 est basée sur l'actuelle incertitude quant à la possibilité pour PostFinance, pour être admissible à la catégorie 3. Il est également ne pas clair dans quelle mesure le modèle d'affaires de PostFinance, unique en son genre, ayant pour mandat de fournir des services de base dans les paiements sont envisageables dans le cadre du programme. Avec cette façon de procéder, PostFinance minimisera le risque pour l'entreprise, les clients et les employés d'entrer en conflit avec les autorités étrangères. Si vous décidez de passer à la catégorie 3, il va le faire entre le 1 juillet et 31 octobre 2014.

Porte-parole de postFinance : Tél. 058 338 32 30.

Pathogens in Plants

a Consumption of fresh produce has increased in recent years, prompted by healthy eating campaigns in the USA, Europe and other parts of the world. However, compared to previous years, fruit and vegetables are now being identified more frequently as the source of a growing number of outbreaks associated with zoonotic pathogens.Between 2003 and 2008, the food vehicles identified in 1,565 outbreaks reported to the Centers for Disease Control and Prevention (CDC) are a broad spectrum of animal- and plant-derived foods (picture 1). The list of implicated foods is regularly expanded as new ones are identified during outbreak investigations. Between 2006 and early 2012, 15 new specific food types were identified as food vehicles in outbreaks affecting the United States. It is curious that while many of the pathogens have animal reservoirs, many new food vehicles are plant derived. This includes plant-derived processed foods, like peanut butter, peanut paste, and spinach powder; spices such as black and white pepper; tree nuts and fresh produce items.Consumer demand for greater choice, variety and year-round availability of fruit and vegetables, as well the vogue for convenient ‘ready to serve’ products, such as bagged salads, has driven the globalisation of supply chains and increased pressure on the food industry. Unfortunately, this may compromise safety. The standard of water used for irrigation, as well as hygiene at harvest and during storage, can vary widely between countries, potentially exposing consumers to increased numbers and varied strains of these pathogens.Intensive farming is not new. It is becoming apparent though that lessons learned in livestock farming can also impact fresh produce growing and processing.Zoonotic pathogens are not commonly present in fruit and vegetables in nature. Human intervention and commercial food production practices have brought the two into close proximity.Pathogens may be naturally present in soil, or may become incorporated in the soil from organic wastes added as fertiliser, or by accidental contamination. For example, water supplies used to wash and irrigate crops can be contaminated with faecal material (and its pathogens) by run-off from nearby fields and livestock farming. The risk of contamination under these circumstances is far greater than the chances of accidental contamination caused by the intrusion of wild animals and birds into fields.Pathogens in water used for spraying can remain on fruits and vegetables and survive on these new carriers. Studies have shown that some enteropathogens are quite adept at surviving on the leaf surface (phylloplane). A study showed that E. coli applied to lettuce could be isolated from the plant for a further 15 days. Fruit and vegetable plants react differently to enteropathogens. Some have been shown to actively support their survival, while others resist. Effective washing and exposure to UV radiation can typically deal with surface contamination. While UV radiation is traditionally used to minimise contamination, successful phylloplane bacteria typically colonise sites that are protected from UV, such as the base of structures (trichomes).Pathogens do not always die on leaving the host animal, but may find a new carrier in the form of plants. Plants sprayed with contaminated water, either during growing or processing, can absorb pathogens through any wounds to the flesh. This is a particular issue with popular consumer items such as pre-prepared lettuce and salads. The cut surfaces exude nutrients and supply pathogens with the means to survive, penetrate to the internal tissue and grow – beyond the reach of chemical sanitisers. Internalisation of pathogens into plants may also be possible through stomata and hydathodes (permanently open water pores). Normally used to secrete water from a plant, a study has shown that under certain conditions pathogens can enter leaves through its hydathodes and move into the vascular system, which may even result in the internal translocation of the bacteria inside plants. Furthermore, contaminated irrigation water can be taken up by a plant’s root system and any pathogens can be stored within its flesh.As a result the food industry must innovate and identify for ways to better protect and improve the microbial quality of fruit and vegetable produce.There is little that consumers can do to protect themselves from fruit and vegetable contamination, as these products are often not cooked. Washing them has little effect on any contamination and being invisible to the naked eye it becomes increasingly important to prevent contamination occurring in the first place.In theory, existing regulations and the food industry requirement that all processors and manufacturers implement hazard analysis and critical control point (HACCP) strategies, should prevent environmental contamination reaching the consumer. Overall evidence suggests that actual contamination of fruit and vegetables with pathogens is low. However, any outbreak has the potential to make consumers ill and in rare cases cause death.All HACCP plans should be reviewed regularly. They must deal not only with questioning whether the water at a facility is safe to use, but also if that water source is trusted and protected against potential contamination. Post-harvest contamination is also known to result from poor food handling processes and poor worker hygiene. Processors need to ensure that HACCP plans are robust, documented and perhaps most importantly, implemented. Poorly trained employees are potentially the weakest link in any plan.The food industry has, out of necessity, invested heavily in microbiological testing and surveillance programmes. Fruit and vegetable products can undergo microbiological testing at any stage of the supply chain but are most commonly checked as the end product. This enables processors to identify any pathogen contamination before goods reach the point of sale.An integrated testing programme can verify the microbial quality of products and in the event of contamination being identified, prevent them reaching the consumer. This is preferable to suffering a product recall as a direct result of an outbreak. Product recalls cost the industry more than just money. They also damage consumer confidence and devalue the brand involved.Global supply chains mean that contamination issues in one part of the world can quickly spread. Existing food safety systems have focused on post-harvest safety, hygiene, handling and testing. Improving food safety going forward will likely rely on increased awareness of public health issues and enforcement of regulations in new and developing markets. This should be complemented by increased focus on identifying contaminations earlier, preventative in-field solutions and introducing stricter practices more in line with livestock farming.For further information please visit our Food Safety website.Ron Wacker, PhDGlobal Food Testing Business Development ManagerSGS Germanyt: +49 6039 4696Picture 1: Distribution of illnesses by food type in 1,565 foodborne outbreaks caused by a single food type and reported to CDC's National Foodborne Disease Outbreak Surveillance System, 2003-2008. (Foodborne Website on August 2013)

BFS – Krankenversicherungsprämien-Index 2013 – Prämienwachstum 2012-2013 dämpfte die Entwicklung der verfügbaren Einkommen um 0,1 Prozentpunkte

AppId is over the quota
AppId is over the quota

Krankenversicherungsprämien-Index 2013 – Prämienwachstum 2012-2013 dämpfte die Entwicklung der verfügbaren Einkommen um 0,1 Prozentpunkte

18.11.2013 (BFS) – Der Krankenversicherungsprämien-Index (KVPI) verzeichnete für das Prämienjahr 2013 ein Wachstum von 1,1 Prozent gegenüber dem Vorjahr. Auf der Basis 1999=100 erreichte der KVPI damit einen Indexstand von 170,4 Punkten. Der vom Bundesamt für Statistik (BFS) berechnete KVPI erfasst die Prämienentwicklung der obligatorischen Krankenpflegeversicherung und der Krankenzusatzversicherung. Anhand des KVPI lässt sich die Auswirkung der Prämienentwicklung auf das Wachstum des verfügbaren Einkommens schätzen. Gemäss der KVPI-Modellrechnung dämpften 2013 die steigenden Prämien das Wachstum des verfügbaren Durchschnittseinkommens um 0,1 Prozentpunkte.